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A B S T R A C T
Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body ﬂuids.
The primary infection is usually asymptomatic in the immunocompetent host and it is common among
adolescents and young adults. The symptomatic form appears, in the majority of cases, as a
mononucleosis syndromewith full recoverywithout speciﬁc treatment.We report a case of a 25 years old
woman who presented with hepatitis due to CMV infection and history of omalizumab administration
one month earlier. This recombinant monoclonal antibody is used to control refractory asthma and
chronic spontaneous urticarial as it inhibits human IgE. Despite that, the long course of the disease lead
us to initiate treatment with valganciclovir. The improvement after that was rapid and complete.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Cytomegalovirus (CMV) is a double stranded DNA virus
belonging to the family Herpesviridae, which may be present in
nearly all organs and body ﬂuids. The infection occurs by contact
with saliva, blood, urine, feces, milk, semen or vaginal ﬂuids, with
the possibility of vertical transmission or by organ transplantation.
The primary infection is most common between 15 and 35 years,
and is usually asymptomatic in the immunocompetent individual.
In symptomatic forms, the most common presentation is the
mononucleosis syndrome: fever, sore throat and lymphadenopa-
thy with hepatosplenomegaly, elevated liver enzymes and the
presence of activated lymphocytes. After primary infection the
virus enters a state of latency and reactivation may occur in case of
immunosuppression.
The diagnosis is based on clinical suspicion and serology, since
the virus induces production of IgM and IgG. IgM is the ﬁrst to
appear in the serum and can take up to about 4 weeks, and
continues usually between 30 and 60days. The determination of
IgG avidity index allows the conﬁrmation of recent infection in the
case of both IgG and IgM are positive. Avidity is weaker the more
the infection is recent. The culture of the virus by shell vial method
in blood and urine, and determining virus antigenemia are other
diagnostic techniques which may be used to monitor response to
treatment. Despite the importance of humoral immunity, cellular
immunity is considered more important in the virus control [1],
with both CD8+ cytotoxic and CD4+ helper cells playing a central
role in the resolution of acute infection and in the maintenance of
long-term memory. In vitro studies demonstrated the association
between production of IFN-gamma by the CD8T lymphocytes and
the risk of infection/CMV disease after transplantation [2–5].
Clinical case
A 25 years old Caucasian woman presented to the emergency
department with complaints of fever and productive cough for
8days and several days of anorexia. She had reported mild
odynophagia at the onset of her illness which had resolved. She
had already received antimicrobials as cefuroxime was prescribed
by her family doctor, because of a suspicion of respiratory
infection, but she had no improvement in her symptons. Her past
history included severe chronic urticarial and had her ﬁrst
omalizumab administration in the previous month. She had no
other concomitant medication. She worked in a day care center
with daily contact with children and lived in a villa in the
countryside, with cats and vaccinated and dewormed dogs. Her
vaccination schedule was up to date and she had no recent trips
abroad.
On physical examination she was in good general condition
with normal respiration rate, body temperature of 38 C, blood
pressure of 113/50mmHg and heart rate of 89bpm. She hadwhitish
lesions on the left tonsil of 4mm diameter, but showed no further
changes. Blood tests showed elevated aminotransferases (AST
162U/L, ALT 129U/L), alkaline phosphatase (163U/L), LDH (601U/
L), leukocytes 4.710 ^ 9/L with 47.7% lymphocytes, 41%
neutrophils, 10% monocytes. An abdominal ultrasound revealed
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no abnormalities and the Monospot was negative. The patient was
discharged for follow-upwith Infectious Diseases consultation two
days later.
With no improvement in her symptoms when she was seen by
Infectious Diseases as an outpatient, repeated blood analyzes on
that day that showed a slight increase in aminotransferases (AST
188U/L, ALT 165U/L), alkaline phosphatase (209U/L), LDH (618U/
L), thrombocytopenia (12910^9/L), elevated ESR (27mm/1 st h)
and lymphocytosis (49%) with activated lymphocytes. It was
decided to admit the patient in the ward to maintain under
surveillance. Blood and urine cultures and serologies were
performed. Of these tests, IgG and IgM were positive for CMV
and EBV, as well as IgM for Enterovirus and Coxsackie virus. Those
results were interpreted as false positives because of the frequent
serological cross reactivity between those viruses [6–10]. She had
vaccinal immunity to hepatitis B virus, was hepatitis C antibody
negative and had natural immunity to hepatitis A virus. The
treponemic test FTA was negative as was the HIV test.
The clinical process of the patient was reviewedwith a focus on
the previous results and it was possible to conclude that two years
before she had already IgG to EBV, but had no antibodies (IgG
neither IgM) to CMV. Those past results lead us to request CMV
antigenemia, that was positive, and the IgG avidity test for CMV,
that was weak. Taking into account the clinical picture and the
results obtained it was assumed, as the most probable hypothesis,
a diagnosis of primary CMV infection. At the 3rd day in the ward
her blood analysis showed declined of both alkaline phosphatase
(159U/L) and LDH (585U/L), but the aminotransferases continued
to rise (ALTof 333U/L, AST 282U/L). The clinical casewas discussed
with the Immunoallergology Unit and we reviewed the literature,
and no data allowed us to associate this primary infection with
omalizumab administration a month earlier. Despite that and
given the persistence of evidence of hepatocyte injury, it was
decided to initiate therapy with valganciclovir 900mg every 12h,
orally. There was a rapid improvement, with resolution of
symptoms and progressive decline in aminotransferases. The
patient was discharged after 5 days of hospitalization and she was
re-evaluated in consultation three weeks later, already with full
resolution of the hepatic dysfunction. Six months later she
repeated CMV serology, and at that time she had IgG positive
and IgM negative, results that conﬁrm primary infection.
Discussion
CMV infection in immunocompetent individuals is usually
asymptomatic, with fewdescriptions of dysfunction of one ormore
systems. When symptomatic, gastrointestinal manifestations are
the most frequent. Due to its low frequency, recommendations for
treatment in this population are unclear.
Omalizumab is a recombinant monoclonal antibody that
inhibits human IgE, approved by the FDA and European Medicines
Agency for use in cases of severe refractory asthma and chronic
spontaneous urticaria. Themolecule structure allows its binding to
FceRI receptor present on mast cells and basophils, the same
epitope that is a receptor to free IgE, but do not affect the IgE
already bound to the receptor. That way, it prevents the activation
of these cells and the consequent liberation of pro-inﬂammatory
mediators [11–14]. On the other hand, it also causes a gradual
reduction of FceRI receptor expression, desensitizing cells to
stimulation by allergen [15–17]. Regarded as a relatively safe drug,
phase III trials have demonstrated a very low incidence of adverse
effects [18,19]. In a study, infectious diseases (respiratory and
urinary) were more frequent in the group with omalizumab [18],
with reports of a case of inﬂuenza virus infection [19].
The authors describe a case of CMV hepatitis in patients
receiving therapy with omalizumab. There is no description in the
literature of other cases where such infection occurred in this
context and it is known that this drug acts speciﬁcally onmast cells
and basophils. Whether the omalizumab promoted the CMV
infection is unclear. Because of the disease persistence and
continuing symptoms after several days, we chose to treat the
patientwith valganciclovir. Therewas prompt improvementwhich
suggests that the valganciclovir effectively treated the infection.
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